Right-sided origin of the left main coronary artery: typical variants and their visualization by cardiac computerized tomography.

D. Ropers,D. C. Ping,S. Achenbach

DOI: https://doi.org/10.1016/j.jcmg.2008.04.014

IF: 16.051

2008-09-01

JACC Cardiovascular Imaging

Abstract:

What problem does this paper attempt to address?

Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024

Ruth Link-Gelles,Elizabeth A.K. Rowley,Malini B. DeSilva,Kristin Dascomb,Stephanie A. Irving,Nicola P. Klein,Shaun J. Grannis,Toan C. Ong,Zachary A. Weber,Katherine E. Fleming-Dutra,Charlene E. McEvoy,Omobosola Akinsete,Daniel Bride,Tamara Sheffield,Allison L. Naleway,Ousseny Zerbo,Bruce Fireman,John Hansen,Kristin Goddard,Brian E. Dixon,Colin Rogerson,William F. Fadel,Thomas Duszynski,Suchitra Rao,Michelle A. Barron,Sarah E. Reese,Sarah W. Ball,Margaret M. Dunne,Karthik Natarajan,Erica Okwuazi,Ami B. Shah,Ryan Wiegand,Mark W. Tenforde,Amanda B. Payne

DOI: https://doi.org/10.15585/mmwr.mm7312a5

2024-03-30

MMWR Morbidity and Mortality Weekly Report

Abstract:This report describes the effectiveness of the updated COVID-19 vaccine in preventing hospitalizations in adults with immunocompromising conditions.

public, environmental & occupational health
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity — IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024

Kevin C. Ma,Diya Surie,Adam S. Lauring,Emily T. Martin,Aleda M. Leis,Leigh Papalambros,Manjusha Gaglani,Christie Columbus,Robert L. Gottlieb,Shekhar Ghamande,Ithan D. Peltan,Samuel M. Brown,Adit A. Ginde,Nicholas M. Mohr,Kevin W. Gibbs,David N. Hager,Safa Saeed,Matthew E. Prekker,Michelle Ng Gong,Amira Mohamed,Nicholas J. Johnson,Vasisht Srinivasan,Jay S. Steingrub,Akram Khan,Catherine L. Hough,Abhijit Duggal,Jennifer G. Wilson,Nida Qadir,Steven Y. Chang,Christopher Mallow,Jennie H. Kwon,Bijal Parikh,Matthew C. Exline,Ivana A. Vaughn,Mayur Ramesh,Basmah Safdar,Jarrod Mosier,Estelle S. Harris,Nathan I. Shapiro,Jamie Felzer,Yuwei Zhu,Carlos G. Grijalva,Natasha Halasa,James D. Chappell,Kelsey N. Womack,Jillian P. Rhoads,Adrienne Baughman,Sydney A. Swan,Cassandra A. Johnson,Todd W. Rice,Jonathan D. Casey,Paul W. Blair,Jin H. Han,Sascha Ellington,Nathaniel M. Lewis,Natalie Thornburg,Clinton R. Paden,Lydia J. Atherton,Wesley H. Self,Fatimah S. Dawood,Jennifer DeCuir

DOI: https://doi.org/10.1101/2024.06.04.24308470

2024-06-05

Abstract:Assessing COVID-19 vaccine effectiveness (VE) and severity of SARS-CoV-2 variants can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to collectively as "JN lineages"), emerged in late 2023 and exhibited substantial genomic divergence from co-circulating XBB lineages. We analyzed patients hospitalized with COVID-19–like illness at 26 hospitals in 20 U.S. states admitted October 18, 2023–March 9, 2024. Using a test-negative, case-control design, we estimated the effectiveness of an updated 2023–2024 (Monovalent XBB.1.5) COVID-19 vaccine dose against sequence-confirmed XBB and JN lineage hospitalization using logistic regression. Odds of severe outcomes, including intensive care unit (ICU) admission and invasive mechanical ventilation (IMV) or death, were compared for JN versus XBB lineage hospitalizations using logistic regression. 585 case-patients with XBB lineages, 397 case-patients with JN lineages, and 4,580 control-patients were included. VE in the first 7–89 days after receipt of an updated dose was 54.2% (95% CI = 36.1%–67.1%) against XBB lineage hospitalization and 32.7% (95% CI = 1.9%–53.8%) against JN lineage hospitalization. Odds of ICU admission (adjusted odds ratio [aOR] 0.80; 95% CI = 0.46–1.38) and IMV or death (aOR 0.69; 95% CI = 0.34–1.40) were not significantly different among JN compared to XBB lineage hospitalizations. Updated 2023–2024 COVID-19 vaccination provided protection against both XBB and JN lineage hospitalization, but protection against the latter may be attenuated by immune escape. Clinical severity of JN lineage hospitalizations was not higher relative to XBB lineage hospitalizations.
Effectiveness Over Time of a Primary Series of the Original Monovalent COVID-19 Vaccines in Adults in the United States

J. Bradley Layton,Patricia C Lloyd,Lauren S Peetluk,Yixin Jiao,Djeneba Audrey Djibo,Joann F Gruber,Jie Deng,Christine Bui,An-Chi Lo,Rachel P Ogilvie,Ron Parambi,Michael E Miller,Jennifer Song,Lisa B Weatherby,Sylvia Cho,Hui Lee Wong,Tainya C Clarke,Jessica Rose Hervol,Dóra Illei,Elizabeth J Bell,Grace Wenya Yang,John D Seeger,Michael Wernecke,Morgan M Richey,Richard A Forshee,Steven A Anderson,Yoganand Chillarige,Cheryl N McMahill-Walraven,Kandace L Amend,Mary S Anthony,Azadeh Shoaibi

DOI: https://doi.org/10.1101/2024.07.24.24310878

2024-07-24

Abstract:With data from 2 US claims databases (Optum, CVS Health) supplemented with Immunization Information System COVID 19 vaccine records, we evaluated overall and time-specific vaccine effectiveness (VE) of an initial primary series for 3 monovalent COVID 19 vaccines—BNT162b2, mRNA-1273, and JNJ-7836735—in adults (18-64 years). Vaccinated individuals were matched to unvaccinated comparators, and we estimated VE against any medically diagnosed COVID 19 and hospital/emergency department (ED)-diagnosed COVID 19. Additionally, we estimated VE by era of predominant variants, in subgroups, and compared across vaccine brands. The cohorts consisted of 341,097 (Optum) and 1,151,775 (CVS Health) matched pairs for BNT162b2; 201,604 (Optum) and 651,545 (CVS Health) for mRNA-1273; and 49,285 (Optum) and 149,813 (CVS Health) for JNJ-7836735. Summary VE estimates from meta-analysis against hospital/ED-diagnosed COVID 19 were: BNT162b2, 77% (95% CI, 76%-78%); mRNA-1273, 84% (95% CI, 83%-85%), JNJ-7836735 66% (95% CI, 63%-68%). VE estimates were higher for hospital/ED-diagnosed COVID 19 than for medically diagnosed COVID-19, and VE estimates were highest in adults receiving mRNA-1273 for both outcomes. VE was sustained for approximately 7 months for medically-diagnosed and up to 9 months for hospital/ED-diagnosed COVID 19. VE differed by brand and variant era. Additional real-world research is needed as new variants and recommendations for updated vaccines have evolved.

Public and Global Health
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

Nicola P. Klein,Melissa S. Stockwell,Maria Demarco,Manjusha Gaglani,Anupam B. Kharbanda,Stephanie A. Irving,Suchitra Rao,Shaun J. Grannis,Kristin Dascomb,Kempapura Murthy,Elizabeth A. Rowley,Alexandra F. Dalton,Malini B. DeSilva,Brian E. Dixon,Karthik Natarajan,Edward Stenehjem,Allison L. Naleway,Ned Lewis,Toan C. Ong,Palak Patel,Deepika Konatham,Peter J. Embi,Sarah E. Reese,Jungmi Han,Nancy Grisel,Kristin Goddard,Michelle A. Barron,Monica Dickerson,I-Chia Liao,William F. Fadel,Duck-Hye Yang,Julie Arndorfer,Bruce Fireman,Eric P. Griggs,Nimish R. Valvi,Carly Hallowell,Ousseny Zerbo,Sue Reynolds,Jill Ferdinands,Mehiret H. Wondimu,Jeremiah Williams,Catherine H. Bozio,Ruth Link-Gelles,Eduardo Azziz-Baumgartner,Stephanie J. Schrag,Mark G. Thompson,Jennifer R. Verani

DOI: https://doi.org/10.15585/mmwr.mm7109e3

2022-03-04

Abstract:The efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine against laboratory-confirmed COVID-19 exceeded 90% in clinical trials that included children and adolescents aged 5-11, 12-15, and 16-17 years (1-3). Limited real-world data on 2-dose mRNA vaccine effectiveness (VE) in persons aged 12-17 years (referred to as adolescents in this report) have also indicated high levels of protection against SARS-CoV-2 (the virus that causes COVID-19) infection and COVID-19-associated hospitalization (4-6); however, data on VE against the SARS-CoV-2 B.1.1.529 (Omicron) variant and duration of protection are limited. Pfizer-BioNTech VE data are not available for children aged 5-11 years. In partnership with CDC, the VISION Network* examined 39,217 emergency department (ED) and urgent care (UC) encounters and 1,699 hospitalizations† among persons aged 5-17 years with COVID-19-like illness across 10 states during April 9, 2021-January 29, 2022,§ to estimate VE using a case-control test-negative design. Among children aged 5-11 years, VE against laboratory-confirmed COVID-19-associated ED and UC encounters 14-67 days after dose 2 (the longest interval after dose 2 in this age group) was 46%. Among adolescents aged 12-15 and 16-17 years, VE 14-149 days after dose 2 was 83% and 76%, respectively; VE ≥150 days after dose 2 was 38% and 46%, respectively. Among adolescents aged 16-17 years, VE increased to 86% ≥7 days after dose 3 (booster dose). VE against COVID-19-associated ED and UC encounters was substantially lower during the Omicron predominant period than the B.1.617.2 (Delta) predominant period among adolescents aged 12-17 years, with no significant protection ≥150 days after dose 2 during Omicron predominance. However, in adolescents aged 16-17 years, VE during the Omicron predominant period increased to 81% ≥7 days after a third booster dose. During the full study period, including pre-Delta, Delta, and Omicron predominant periods, VE against laboratory-confirmed COVID-19-associated hospitalization among children aged 5-11 years was 74% 14-67 days after dose 2, with wide CIs that included zero. Among adolescents aged 12-15 and 16-17 years, VE 14-149 days after dose 2 was 92% and 94%, respectively; VE ≥150 days after dose 2 was 73% and 88%, respectively. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations, including a booster dose for those aged 12-17 years.

public, environmental & occupational health
Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

Nathaniel M Lewis,Wesley H Self,Manjusha Gaglani,Adit A Ginde,David J Douin,H Keipp Talbot,Jonathan D Casey,Nicholas M Mohr,Anne Zepeski,Shekhar A Ghamande,Tresa A McNeal,Nathan I Shapiro,Kevin W Gibbs,D Clark Files,David N Hager,Arber Shehu,Matthew E Prekker,Heidi L Erickson,Michelle N Gong,Amira Mohamed,Nicholas J Johnson,Vasisht Srinivasan,Jay S Steingrub,Ithan D Peltan,Samuel M Brown,Emily T Martin,Arnold S Monto,Akram Khan,Laurence W Busse,Caitlin C Ten Lohuis,Abhijit Duggal,Jennifer G Wilson,Alexandra June Gordon,Nida Qadir,Steven Y Chang,Christopher Mallow,Carolina Rivas,Hilary M Babcock,Jennie H Kwon,Matthew C Exline,Adam S Lauring,Natasha Halasa,James D Chappell,Carlos G Grijalva,Todd W Rice,Jillian P Rhoads,Ian D Jones,William B Stubblefield,Adrienne Baughman,Kelsey N Womack,Christopher J Lindsell,Kimberly W Hart,Yuwei Zhu,Katherine Adams,Manish M Patel,Mark W Tenforde,IVY Network Collaborators

DOI: https://doi.org/10.1093/cid/ciac439

2022-10-03

Abstract:Background . Adults in the United States (US) began receiving the adenovirus vector coronavirus disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness (VE) against COVID-19 hospitalization and high disease severity during the first 10 months of its use. Methods . In a multicenter case-control analysis of US adults (≥18 years) hospitalized 11 March to 15 December 2021, we estimated VE against susceptibility to COVID-19 hospitalization (VEs), comparing odds of prior vaccination with a single dose Ad26.COV2.S vaccine between hospitalized cases with COVID-19 and controls without COVID-19. Among hospitalized patients with COVID-19, we estimated VE against disease progression (VEp) to death or invasive mechanical ventilation (IMV), comparing odds of prior vaccination between patients with and without progression. Results . After excluding patients receiving mRNA vaccines, among 3979 COVID-19 case-patients (5% vaccinated with Ad26.COV2.S) and 2229 controls (13% vaccinated with Ad26.COV2.S), VEs of Ad26.COV2.S against COVID-19 hospitalization was 70% (95% confidence interval [CI]: 63-75%) overall, including 55% (29-72%) among immunocompromised patients, and 72% (64-77%) among immunocompetent patients, for whom VEs was similar at 14-90 days (73% [59-82%]), 91-180 days (71% [60-80%]), and 181-274 days (70% [54-81%]) postvaccination. Among hospitalized COVID-19 case-patients, VEp was 46% (18-65%) among immunocompetent patients. Conclusions . The Ad26.COV2.S COVID-19 vaccine reduced the risk of COVID-19 hospitalization by 72% among immunocompetent adults without waning through 6 months postvaccination. After hospitalization for COVID-19, vaccinated immunocompetent patients were less likely to require IMV or die compared to unvaccinated immunocompetent patients.
Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021

Peter J Embi,Matthew E Levy,Palak Patel,Malini B DeSilva,Manjusha Gaglani,Kristin Dascomb,Margaret M Dunne,Nicola P Klein,Toan C Ong,Shaun J Grannis,Karthik Natarajan,Duck-Hye Yang,Edward Stenehjem,Ousseny Zerbo,Charlene McEvoy,Suchitra Rao,Mark G Thompson,Deepika Konatham,Stephanie A Irving,Brian E Dixon,Jungmi Han,Kristin E Schrader,Nancy Grisel,Ned Lewis,Anupam B Kharbanda,Michelle A Barron,Sue Reynolds,I-Chia Liao,William F Fadel,Elizabeth A Rowley,Julie Arndorfer,Kristin Goddard,Kempapura Murthy,Nimish R Valvi,Zachary A Weber,Bruce Fireman,Sarah E Reese,Sarah W Ball,Allison L Naleway

DOI: https://doi.org/10.1016/j.vaccine.2023.05.038

IF: 4.169

2023-08-23

Vaccine

Abstract:Background: Immunocompromised (IC) persons are at increased risk for severe COVID-19 outcomes and are less protected by 1-2 COVID-19 vaccine doses than are immunocompetent (non-IC) persons. We compared vaccine effectiveness (VE) against medically attended COVID-19 of 2-3 mRNA and 1-2 viral-vector vaccine doses between IC and non-IC adults. Methods: Using a test-negative design among eight VISION Network sites, VE against laboratory-confirmed COVID-19-associated emergency department (ED) or urgent care (UC) events and hospitalizations from 26 August-25 December 2021 was estimated separately among IC and non-IC adults and among specific IC condition subgroups. Vaccination status was defined using number and timing of doses. VE for each status (versus unvaccinated) was adjusted for age, geography, time, prior positive test result, and local SARS-CoV-2 circulation. Results: We analyzed 8,848 ED/UC events and 18,843 hospitalizations among IC patients and 200,071 ED/UC events and 70,882 hospitalizations among non-IC patients. Among IC patients, 3-dose mRNA VE against ED/UC (73% [95% CI: 64-80]) and hospitalization (81% [95% CI: 76-86]) was lower than that among non-IC patients (ED/UC: 94% [95% CI: 93-94]; hospitalization: 96% [95% CI: 95-97]). Similar patterns were observed for viral-vector vaccines. Transplant recipients had lower VE than other IC subgroups. Conclusions: During B.1.617.2 (Delta) variant predominance, IC adults received moderate protection against COVID-19-associated medical events from three mRNA doses, or one viral-vector dose plus a second dose of any product. However, protection was lower in IC versus non-IC patients, especially among transplant recipients, underscoring the need for additional protection among IC adults.
Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States

Aaron M Frutos,Ashley M Price,Elizabeth Harker,Emily L Reeves,Haris M Ahmad,Vel Murugan,Emily T Martin,Stacey House,Elie A Saade,Richard K Zimmerman,Manjusha Gaglani,Karen J Wernli,Emmanuel B Walter,Marian G Michaels,Mary A Staat,Geoffrey A Weinberg,Rangaraj Selvarangan,Julie A Boom,Eileen J Klein,Natasha B Halasa,Adit A Ginde,Kevin W Gibbs,Yuwei Zhu,Wesley H Self,Sara Y Tartof,Nicola P Klein,Kristin Dascomb,Malini B DeSilva,Zachary A Weber,Duck-Hye Yang,Sarah W Ball,Diya Surie,Jennifer DeCuir,Fatimah S Dawood,Heidi L Moline,Ariana P Toepfer,Benjamin R Clopper,Ruth Link-Gelles,Amanda B Payne,Jessie R Chung,Brendan Flannery,Nathaniel M Lewis,Samantha M Olson,Katherine Adams,Mark W Tenforde,Shikha Garg,Lisa A Grohskopf,Carrie Reed,Sascha Ellington,CDC Influenza Vaccine Effectiveness Collaborators,Adam S Lauring,Julie Arndorfer,Daniel Bride,Ithan D Peltan,Nicholas M Mohr,David N Hager,Matthew Prekker,Amira Mohamed,Nicholas Johnson,Jay Steingrub,Akram Khan,Laurence W Busse,Abhijit Duggal,Jennifer G Wilson,Nida Qadir,Christopher Mallow,Jennie H Kwon,Matthew C Exline,Nathan I Shapiro,Cristie Columbus,Ivana A Vaughan,Jarrod M Mosier,Basmah Safdar,Estelle S Harris,James D Chappell,Laura S Stewart,Sydney A Swan,Pedro A Piedra,Leila C Sahni,Janet A Englund,Danielle M Zerr,Robert W Hickey,John V Williams,Chelsea Rohlfs,Elizabeth P Schlaudecker,Dinah Dosdos,Mary E Moffatt,Jennifer E Schuster,Kirsten Weltmer,Peter G Szilagyi,Tara Curley,Jamie Mills,Kiran Faryar,Robert A Salata,Krissy Moehling Geffel,Mary Patricia Nowalk,Kempapura Murthy,Spencer Rose,Michael E Smith,Brianna Wickersham,Brian D Williamson,Natalie A B Bontrager,Olivia L Williams,Joanna L Kramer,Lora Nordstrom,Arnold S Monto,Ivana A Vaughn,Monica Dickerson,Callie McLean,Emma K Noble,Caitlin Ray,Kelsey Sumner,Inih Essien,Linda Fletcher,Phillip Heaton,Sheryl Kane,Charlene McEvoy,Sunita Thapa,Gabriela Vazquez-Benitez,Cassandra Bezi,Richard Contreras,Gregg S Davis,Bruno J Lewin,Parag Mahale,Rudy Patrick,Lei Qian,Emily Rayens,Iris Anne C Reyes,Denison S Ryan,S Bianca Salas,Lina S Sy,Meiyu Yeh,Xi Zeng,Bruce Fireman,Kristin Goddard,John Hansen,Karen B Jacobson,Julius Timbol,Ousseny Zerbo,Margaret Dunne,Yan Zhuang

DOI: https://doi.org/10.15585/mmwr.mm7308a3

2024-02-29

Abstract:In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months. Using data from four vaccine effectiveness (VE) networks during the 2023-24 influenza season, interim influenza VE was estimated among patients aged ≥6 months with acute respiratory illness-associated medical encounters using a test-negative case-control study design. Among children and adolescents aged 6 months-17 years, VE against influenza-associated outpatient visits ranged from 59% to 67% and against influenza-associated hospitalization ranged from 52% to 61%. Among adults aged ≥18 years, VE against influenza-associated outpatient visits ranged from 33% to 49% and against hospitalization from 41% to 44%. VE against influenza A ranged from 46% to 59% for children and adolescents and from 27% to 46% for adults across settings. VE against influenza B ranged from 64% to 89% for pediatric patients in outpatient settings and from 60% to 78% for all adults across settings. These findings demonstrate that the 2023-24 seasonal influenza vaccine is effective at reducing the risk for medically attended influenza virus infection. CDC recommends that all persons aged ≥6 months who have not yet been vaccinated this season get vaccinated while influenza circulates locally.
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022

Amadea Britton,Peter J Embi,Matthew E Levy,Manjusha Gaglani,Malini B DeSilva,Brian E Dixon,Kristin Dascomb,Palak Patel,Kristin E Schrader,Nicola P Klein,Toan C Ong,Karthik Natarajan,Emily Hartmann,Anupam B Kharbanda,Stephanie A Irving,Monica Dickerson,Margaret M Dunne,Chandni Raiyani,Shaun J Grannis,Edward Stenehjem,Ousseny Zerbo,Suchitra Rao,Jungmi Han,Chantel Sloan-Aagard,Eric P Griggs,Zachary A Weber,Kempapura Murthy,William F Fadel,Nancy Grisel,Charlene McEvoy,Ned Lewis,Michelle A Barron,Juan Nanez,Sarah E Reese,Mufaddal Mamawala,Nimish R Valvi,Julie Arndorfer,Kristin Goddard,Duck-Hye Yang,Bruce Fireman,Sarah W Ball,Ruth Link-Gelles,Allison L Naleway,Mark W Tenforde

DOI: https://doi.org/10.15585/mmwr.mm7142a4

2022-10-21

Abstract:Persons with moderate-to-severe immunocompromising conditions might have reduced protection after COVID-19 vaccination, compared with persons without immunocompromising conditions (1-3). On August 13, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended that adults with immunocompromising conditions receive an expanded primary series of 3 doses of an mRNA COVID-19 vaccine. ACIP followed with recommendations on September 23, 2021, for a fourth (booster) dose and on September 1, 2022, for a new bivalent mRNA COVID-19 vaccine booster dose, containing components of the BA.4 and BA.5 sublineages of the Omicron (B.1.1.529) variant (4). Data on vaccine effectiveness (VE) of monovalent COVID-19 vaccines among persons with immunocompromising conditions since the emergence of the Omicron variant in December 2021 are limited. In the multistate VISION Network,§ monovalent 2-, 3-, and 4-dose mRNA VE against COVID-19-related hospitalization were estimated among adults with immunocompromising conditions¶ hospitalized with COVID-19-like illness,** using a test-negative design comparing odds of previous vaccination among persons with a positive or negative molecular test result (case-patients and control-patients) for SARS-CoV-2 (the virus that causes COVID-19). During December 16, 2021-August 20, 2022, among SARS-CoV-2 test-positive case-patients, 1,815 (36.3%), 1,387 (27.7%), 1,552 (31.0%), and 251 (5.0%) received 0, 2, 3, and 4 mRNA COVID-19 vaccine doses, respectively. Among test-negative control-patients during this period, 6,928 (23.7%), 7,411 (25.4%), 12,734 (43.6%), and 2,142 (7.3%) received these respective doses. Overall, VE against COVID-19-related hospitalization among adults with immunocompromising conditions hospitalized for COVID-like illness during Omicron predominance was 36% ≥14 days after dose 2, 69% 7-89 days after dose 3, and 44% ≥90 days after dose 3. Restricting the analysis to later periods when Omicron sublineages BA.2/BA.2.12.1 and BA.4/BA.5 were predominant and 3-dose recipients were eligible to receive a fourth dose, VE was 32% ≥90 days after dose 3 and 43% ≥7 days after dose 4. Protection offered by vaccination among persons with immunocompromising conditions during Omicron predominance was moderate even after a 3-dose monovalent primary series or booster dose. Given the incomplete protection against hospitalization afforded by monovalent COVID-19 vaccines, persons with immunocompromising conditions might benefit from updated bivalent vaccine booster doses that target recently circulating Omicron sublineages, in line with ACIP recommendations. Further, additional protective recommendations for persons with immunocompromising conditions, including the use of prophylactic antibody therapy, early access to and use of antivirals, and enhanced nonpharmaceutical interventions such as well-fitting masks or respirators, should also be considered.
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Mark G. Thompson,Karthik Natarajan,Stephanie A. Irving,Elizabeth A. Rowley,Eric P. Griggs,Manjusha Gaglani,Nicola P. Klein,Shaun J. Grannis,Malini B. DeSilva,Edward Stenehjem,Sarah E. Reese,Monica Dickerson,Allison L. Naleway,Jungmi Han,Deepika Konatham,Charlene McEvoy,Suchitra Rao,Brian E. Dixon,Kristin Dascomb,Ned Lewis,Matthew E. Levy,Palak Patel,I-Chia Liao,Anupam B. Kharbanda,Michelle A. Barron,William F. Fadel,Nancy Grisel,Kristin Goddard,Duck-Hye Yang,Mehiret H. Wondimu,Kempapura Murthy,Nimish R. Valvi,Julie Arndorfer,Bruce Fireman,Margaret M. Dunne,Peter Embi,Eduardo Azziz-Baumgartner,Ousseny Zerbo,Catherine H. Bozio,Sue Reynolds,Jill Ferdinands,Jeremiah Williams,Ruth Link-Gelles,Stephanie J. Schrag,Jennifer R. Verani,Sarah Ball,Toan C. Ong

DOI: https://doi.org/10.15585/mmwr.mm7104e3

2022-01-21

Abstract:Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months (1,2) because of waning vaccine induced immunity over time,* possible increased immune evasion by SARS-CoV-2 variants (3), or a combination of these and other factors. CDC recommends that all persons aged ≥12 years receive a third dose (booster) of an mRNA vaccine ≥5 months after receipt of the second mRNA vaccine dose and that immunocompromised individuals receive a third primary dose.† A third dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine increases neutralizing antibody levels (4), and three recent studies from Israel have shown improved effectiveness of a third dose in preventing COVID-19 associated with infections with the SARS-CoV-2 B.1.617.2 (Delta) variant (5-7). Yet, data are limited on the real-world effectiveness of third doses of COVID-19 mRNA vaccine in the United States, especially since the SARS-CoV-2 B.1.1.529 (Omicron) variant became predominant in mid-December 2021. The VISION Network§ examined VE by analyzing 222,772 encounters from 383 emergency departments (EDs) and urgent care (UC) clinics and 87,904 hospitalizations from 259 hospitals among adults aged ≥18 years across 10 states from August 26, 2021¶ to January 5, 2022. Analyses were stratified by the period before and after the Omicron variant became the predominant strain (>50% of sequenced viruses) at each study site. During the period of Delta predominance across study sites in the United States (August-mid-December 2021), VE against laboratory-confirmed COVID-19-associated ED and UC encounters was 86% 14-179 days after dose 2, 76% ≥180 days after dose 2, and 94% ≥14 days after dose 3. Estimates of VE for the same intervals after vaccination during Omicron variant predominance were 52%, 38%, and 82%, respectively. During the period of Delta variant predominance, VE against laboratory-confirmed COVID-19-associated hospitalizations was 90% 14-179 days after dose 2, 81% ≥180 days after dose 2, and 94% ≥14 days after dose 3. During Omicron variant predominance, VE estimates for the same intervals after vaccination were 81%, 57%, and 90%, respectively. The highest estimates of VE against COVID-19-associated ED and UC encounters or hospitalizations during both Delta- and Omicron-predominant periods were among adults who received a third dose of mRNA vaccine. All unvaccinated persons should get vaccinated as soon as possible. All adults who have received mRNA vaccines during their primary COVID-19 vaccination series should receive a third dose when eligible, and eligible persons should stay up to date with COVID-19 vaccinations.
Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking.

R. Hurt,J. Krook,I. Croghan,C. Loprinzi,J. Sloan,P. Novotny,C. Kardinal,J. Knost,M. Tirona,F. Addo,R. Morton,J. Michalak,P. Schaefer,Patricia A Porter,P. Stella

DOI: https://doi.org/10.1200/JCO.2003.08.160

IF: 45.3

2003-03-01

Journal of Clinical Oncology

Abstract:PURPOSE To determine whether (1) tailored nicotine patch therapy that is based on smoking rate can be carried out in a multisite oncology investigative group practice setting, (2) long-term use of bupropion reduces the rate of relapse to smoking in smokers who stop smoking with nicotine patch therapy, and (3) bupropion can initiate smoking abstinence among smokers who have failed to stop smoking after nicotine patch therapy. PARTICIPANTS AND METHODS Fourteen North Central Cancer Treatment Group sites recruited generally healthy adult smokers from the general population for nicotine patch therapy and based the patch dosage on smoking rates. At completion of nicotine patch therapy, nonsmoking participants were eligible to be assigned to bupropion or placebo for 6 months (for relapse prevention). and smoking participants were eligible to be assigned to bupropion or placebo for 8 weeks of treatment. RESULTS Of 578 subjects, 31% were abstinent from smoking at the end of nicotine patch therapy. Of those subjects not smoking at the end of nicotine patch therapy who entered the relapse prevention phase, 28% and 25% were not smoking at 6 months (the end of the medication phase) for bupropion and placebo, respectively (P =.73). For those still smoking at the end of nicotine patch therapy, 3.1% and 0.0% stopped smoking with bupropion or placebo, respectively (P =.12). CONCLUSION Tailored nicotine patch therapy for the general population of smokers can be provided in a multisite oncology investigative group setting. Bupropion did not reduce relapse to smoking in smokers who stopped smoking with nicotine patch therapy. Bupropion did not initiate abstinence among smokers who failed to stop smoking with nicotine patch therapy.
Effectiveness of the Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters in Pregnant Persons Who Were Not Immunocompromised: VISION Network, June 2022-August 2023

Allison Avrich Ciesla,Victoria Lazariu,Kristin Dascomb,Stephanie A Irving,Brian E Dixon,Manjusha Gaglani,Allison L Naleway,Shaun J Grannis,Sarah Ball,Anupam B Kharbanda,Gabriela Vazquez-Benitez,Nicola P Klein,Karthik Natarajan,Toan C Ong,Peter J Embi,Katherine E Fleming-Dutra,Ruth Link-Gelles,Ousseny Zerbo

DOI: https://doi.org/10.1093/ofid/ofae481

2024-08-28

Abstract:Pregnant people face increased risk of severe COVID-19. Current guidelines recommend updated COVID-19 vaccination (2023-2024) for those aged ≥6 months, irrespective of pregnancy status. To refine recommendations for pregnant people, further data are needed. Using a test-negative design, we evaluated COVID-19 vaccine effectiveness against medically attended COVID-19 with COVID-19-like illness among pregnant people aged 18 to 45 years during June 2022 to August 2023. When doses were received during pregnancy, vaccine effectiveness was 52% (95% CI, 29%-67%); when received <6 months prior to pregnancy, 28% (95% CI, 11%-42%); and when received ≥6 months prior to pregnancy, 6% (95% CI, -11% to 21%). Pregnant people should stay up-to-date with recommended COVID-19 vaccination.
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023

Ruth Link-Gelles,Zachary A. Weber,Sarah E. Reese,Amanda B. Payne,Manjusha Gaglani,Katherine Adams,Anupam B. Kharbanda,Karthik Natarajan,Malini B. DeSilva,Kristin Dascomb,Stephanie A. Irving,Nicola P. Klein,Shaun J. Grannis,Toan C. Ong,Peter J. Embi,Margaret M. Dunne,Monica Dickerson,Charlene McEvoy,Julie Arndorfer,Allison L. Naleway,Kristin Goddard,Brian E. Dixon,Eric P. Griggs,John Hansen,Nimish Valvi,Morgan Najdowski,Julius Timbol,Colin Rogerson,Bruce Fireman,William F. Fadel,Palak Patel,Caitlin S. Ray,Ryan Wiegand,Sarah Ball,Mark W. Tenforde

DOI: https://doi.org/10.15585/mmwr.mm7221a3

2023-05-27

Abstract:This report describes durability of protection for bivalent COVID-19 vaccination among immunocompromised adults.

public, environmental & occupational health
Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024

Ruth Link-Gelles,Allison Avrich Ciesla,Josephine Mak,Joseph D. Miller,Benjamin J. Silk,Anastasia S. Lambrou,Clinton R. Paden,Philip Shirk,Amadea Britton,Zachary R. Smith,Katherine E. Fleming-Dutra

DOI: https://doi.org/10.15585/mmwr.mm7304a2

2024-02-02

MMWR Morbidity and Mortality Weekly Report

Abstract:This report describes vaccine effectiveness for the updated COVID-19 vaccine in preventing symptomatic SARS-CoV-2 infection.

public, environmental & occupational health
Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents

Samantha M. Olson,Margaret M. Newhams,Natasha B. Halasa,Ashley M. Price,Julie A. Boom,Leila C. Sahni,Pia S. Pannaraj,Katherine Irby,Tracie C. Walker,Stephanie P. Schwartz,Aline B. Maddux,Elizabeth H. Mack,Tamara T. Bradford,Jennifer E. Schuster,Ryan A. Nofziger,Melissa A. Cameron,Kathleen Chiotos,Melissa L. Cullimore,Shira J. Gertz,Emily R. Levy,Michele Kong,Natalie Z. Cvijanovich,Mary A. Staat,Satoshi Kamidani,Brandon M. Chatani,Samina S. Bhumbra,Katherine E. Bline,Mary G. Gaspers,Charlotte V. Hobbs,Sabrina M. Heidemann,Mia Maamari,Heidi R. Flori,Janet R. Hume,Matt S. Zinter,Kelly N. Michelson,Laura D. Zambrano,Angela P. Campbell,Manish M. Patel,Adrienne G. Randolph

DOI: https://doi.org/10.1056/nejmoa2117995

IF: 158.5

2022-02-24

New England Journal of Medicine

Abstract:BACKGROUND: The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019 (Covid-19) caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States has offered an opportunity to assess the real-world effectiveness of the BNT162b2 messenger RNA vaccine in adolescents between 12 and 18 years of age.METHODS: We used a case-control, test-negative design to assess vaccine effectiveness against Covid-19 resulting in hospitalization, admission to an intensive care unit (ICU), the use of life-supporting interventions (mechanical ventilation, vasopressors, and extracorporeal membrane oxygenation), or death. Between July 1 and October 25, 2021, we screened admission logs for eligible case patients with laboratory-confirmed Covid-19 at 31 hospitals in 23 states. We estimated vaccine effectiveness by comparing the odds of antecedent full vaccination (two doses of BNT162b2) in case patients as compared with two hospital-based control groups: patients who had Covid-19-like symptoms but negative results on testing for SARS-CoV-2 (test-negative) and patients who did not have Covid-19-like symptoms (syndrome-negative).RESULTS: A total of 445 case patients and 777 controls were enrolled. Overall, 17 case patients (4%) and 282 controls (36%) had been fully vaccinated. Of the case patients, 180 (40%) were admitted to the ICU, and 127 (29%) required life support; only 2 patients in the ICU had been fully vaccinated. The overall effectiveness of the BNT162b2 vaccine against hospitalization for Covid-19 was 94% (95% confidence interval [CI], 90 to 96); the effectiveness was 95% (95% CI, 91 to 97) among test-negative controls and 94% (95% CI, 89 to 96) among syndrome-negative controls. The effectiveness was 98% against ICU admission and 98% against Covid-19 resulting in the receipt of life support. All 7 deaths occurred in patients who were unvaccinated.CONCLUSIONS: Among hospitalized adolescent patients, two doses of the BNT162b2 vaccine were highly effective against Covid-19-related hospitalization and ICU admission or the receipt of life support. (Funded by the Centers for Disease Control and Prevention.).

medicine, general & internal
Effectiveness of the original monovalent mRNA COVID-19 vaccination series against hospitalization for COVID-19-associated venous thromboembolism

David N Hager,Yuwei Zhu,Ine Sohn,William B Stubblefield,Michael B Streiff,Manjusha Gaglani,Jay S Steingrub,Abhijit Duggal,Jamie R Felzer,Mary O'Rourke,Ithan D Peltan,Amira Mohamed,Robin Stiller,Jennifer G Wilson,Nida Qadir,Adit A Ginde,Anne E Zepeski,Christopher Mallow,Adam S Lauring,Nicholas J Johnson,Kevin W Gibbs,Jennie H Kwon,Wesley H Self,For the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network,Manjusha Gaglani,Tresa McNeal,Shekhar Ghamande,Nicole Calhoun,Kempapura Murthy,Judy Herrick,Amanda McKillop,Eric Hoffman,Martha Zayed,Michael Smith,Jay Steingrub,Lori-Ann Kozikowski,Lesley De Souza,Scott Ouellette,Nathan I Shapiro,Michael Bolstad,Brianna Coviello,Robert Ciottone,Arnaldo Devilla,Ana Grafals,Conor Higgins,Carlo Ottanelli,Kimberly Redman,Douglas Scaffidi,Alexander Weingart,Diya Surie,Meredith McMorrow,Jennifer DeCuir,Natalie Thornburg,Brendan Flannery,Nathaniel Lewis,Mark Tenforde,Katherine Adams,Manish Patel,Omar Mehkri,Megan Mitchell,Zachary Griffith,Connery Brennan,Kiran Ashok,Bryan Poynter,Abhijit Duggal,Laurence Busse,Caitlin ten Lohuis,Nicholas Stanley,Sophia Zhang,Matthew Prekker,Heidi Erickson,Anne Frosch,Audrey Hendrickson,Sean Caspers,Walker Tordsen,Olivia Kaus,Tyler Scharber,Ithan Peltan,Samuel Brown,Jenna Lumpkin,Cassie Smith,Hunter Marshall,David N Hager,Harith Ali,Michelle Gong,Amira Mohamed,Rahul Nair,Jen-Ting Tina Chen,Matthew Exline,Sarah Karow,Emily Robart,Paulo Nunes Maldonado,Maryiam Khan,Preston So,Madison So,Elizabeth Schwartz,Mena Botros,Akram Khan,Catherine L Hough,Haeun Jung,Jesus Martinez,Andrea Luong,Bao Huynh,Habiba Ibrahim,Cynthia Villanueva-Vargas,Juliana Villanueva-Vargas,Suha Quadri,Jennifer G Wilson,Alexandra June Gordon,Joe Levitt,Cynthia Perez,Anita Visweswaran,Jonasel Roque,Nida Qadir,Steven Chang,Trevor Frankel,Omai Garner,Sukantha Chandrasekaran,Adit Ginde,David Douin,Kelly Jensen,David Huynh,Aimee Steinwand,Cori Withers,Nicholas Mohr,Anne Zepeski,Paul Nassar,Shannon Landers,Karin Nielsen,Noble Briggs,Cathy Fairfield,Chris Mallow,Carolina Rivas,Emily Martin,Arnold Monto,Adam Lauring,E J McSpadden,Rachel Truscon,Anne Kaniclides,Lara Thomas,Ramsay Bielak,Weronika Damek Valvano,Rebecca Fong,William J Fitzsimmons,Christopher Blair,Julie Gilbert,Leigh Papalambros,Nicholas Johnson,Vasisht Srinivasan,Christine D Crider,Kyle A Steinbock,Thomas C Paulsen,Layla A Anderson,Wesley H Self,H Keipp Talbot,Carlos Grijalva,Ian Jones,Natasha Halasa,James Chappell,Kelsey Womack,Jillian Rhoads,Adrienne Baughman,Christy Kampe,Jakea Johnson,Kim Hart,Todd Rice,Jonathan Casey,William B Stubblefield,Yuwei Zhu,Laura L Short,Lauren J Ezzell,Margaret E Whitsett,Rendie E McHenry,Samarian J Hargrave,Marcia Blair,Jennifer L Luther,Claudia Guevara Pulido,Bryan P M Peterson,D Clark Files,Kevin Gibbs,Mary LaRose,Leigha Landreth,Madeline Hicks,Lisa Parks,Hilary Babcock,Jennie Kwon,Jahnavi Bongu,David McDonald,Candice Cass,Sondra Seiler,David Park,Tiffany Hink,Meghan Wallace,Carey-Ann Burnham,Olivia G Arter

DOI: https://doi.org/10.1093/infdis/jiae502

2024-10-16

The Journal of Infectious Diseases

Abstract:Background COVID-19 is a strong risk factor for venous thromboembolism (VTE). Few studies have evaluated the effectiveness of COVID-19 vaccination in preventing hospitalization for COVID-19 with VTE. Methods Adults hospitalized at 21 sites between March 2021 and October 2022 with symptoms of acute respiratory illness were assessed for COVID-19, completion of the original monovalent mRNA COVID-19 vaccination series, and VTE. Prevalence of VTE was compared between unvaccinated and vaccinated patients with COVID-19. Vaccine effectiveness in preventing COVID-19 hospitalization with VTE was calculated using a test negative design. Vaccine effectiveness was also stratified by predominant circulating SARS-CoV-2 variant. Results Among 18,811 patients (median age 63 [IQR:50-73], 49% women, 59% non-Hispanic White, 20% non-Hispanic Black, 14% Hispanic, and median of 2 comorbid conditions [IQR:1–3]), 9,792 were admitted with COVID-19 (44% vaccinated) and 9,019 were test-negative controls (73% vaccinated). Among patients with COVID-19, 601 were diagnosed with VTE by hospital day 28, of whom 170 were vaccinated. VTE was more common among unvaccinated than vaccinated COVID-19 patients (7.8% versus 4.0%; p=0.001). Vaccine effectiveness against COVID-19 hospitalization with VTE was 84% (95% CI: 80–87%) overall. Vaccine effectiveness stratified by predominant circulating variant was 88% (73-95%) for alpha, 93% (90-95%) for delta, and 68% (58-76%) for omicron variants. Conclusions and Relevance Vaccination with the original monovalent mRNA series was associated with a decrease in COVID-19 hospitalization with VTE, though data detailing prior history of VTE and use of anticoagulation were not available. These findings will inform risk-benefit considerations for those considering vaccination.

immunology,infectious diseases,microbiology
Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023

Jennifer DeCuir,Diya Surie,Yuwei Zhu,Adam S. Lauring,Manjusha Gaglani,Tresa McNeal,Shekhar Ghamande,Ithan D. Peltan,Samuel M. Brown,Adit A. Ginde,Aimee Steinwand,Nicholas M. Mohr,Kevin W. Gibbs,David N. Hager,Harith Ali,Anne Frosch,Michelle N. Gong,Amira Mohamed,Nicholas J. Johnson,Vasisht Srinivasan,Jay S. Steingrub,Akram Khan,Laurence W. Busse,Abhijit Duggal,Jennifer G. Wilson,Nida Qadir,Steven Y. Chang,Christopher Mallow,Jennie H. Kwon,Matthew C. Exline,Nathan I. Shapiro,Cristie Columbus,Ivana A. Vaughn,Mayur Ramesh,Basmah Safdar,Jarrod M. Mosier,Jonathan D. Casey,H. Keipp Talbot,Todd W. Rice,Natasha Halasa,James D. Chappell,Carlos G. Grijalva,Adrienne Baughman,Kelsey N. Womack,Jillian P. Rhoads,Sydney A. Swan,Cassandra Johnson,Nathaniel Lewis,Sascha Ellington,Fatimah S. Dawood,Meredith McMorrow,Wesley H. Self,for the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network

DOI: https://doi.org/10.1111/irv.70027

2024-11-06

Influenza and Other Respiratory Viruses

Abstract:Influenza and Other Respiratory Viruses, Volume 18, Issue 11, November 2024.

infectious diseases,virology
Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study

Freja Cordelia Møller Kirsebom,Julia Stowe,Jamie Lopez Bernal,Alex Allen,Nick Andrews

DOI: https://doi.org/10.1016/j.jinf.2024.106177

IF: 28.2

2024-05-08

Journal of Infection

Abstract:Introduction The last COVID-19 vaccine offered to all adults in England became available from November 2021. The most recent booster programme commenced in September 2023. Bivalent BA.4-5 or monovalent XBB.1.5 boosters were given. During the study period, the JN.1 variant became dominant in England. Methods Vaccine effectiveness against hospitalisation was estimated throughout using the test-negative case-control study design where positive PCR tests from hospitalised individuals are cases and comparable negative PCR tests are controls. Multivariable logistic regression was used to assess vaccine effectiveness against hospitalisation with the test result as the outcome, vaccination status as the primary exposure variable of interest and confounder adjustment. Results There was no evidence of residual protection for boosters given as part of previous campaigns. There were 28,916 eligible tests included to estimate the effectiveness of the autumn 2023 boosters in those aged 65 years and older. VE peaked at 50.6% (95% CI: 44.2-56.3%) after 2-4 weeks, followed by waning to 13.6% (95% CI: -11.7-33.2%). Estimates were generally higher for the XBB.1.5 booster than the BA.4-5 booster, but this difference was not statistically significant. Point estimates were highest against XBB sub-lineages. Effectiveness was lower against both JN.1 and EG.5.1 variants with confidence intervals non-overlapping with the effectiveness of the XBB sub-lineages at 2-4 weeks for EG.5.1 where VE was 44.5% (95% CI: 20.2- 61.4%) and at 5-9 weeks for JN.1 where VE was 26.4% (95%CI: -3.4-47.6%). Conclusions The recent monovalent XBB.1.5 and bivalent BA.4-5 boosters provided comparable and good protection against hospitalisation, however there was evidence of lower VE against hospitalisation of these boosters against JN.1.

infectious diseases
Giardia lamblia and Cryptosporidium infections in child day‐care centers in Fulton County, Georgia

D. Addiss,J. M. Stewart,R. J. Finton,S. Wahlquist,Ruby M. Williams,Jennifer W. Dickerson,H. C. Spencer,D. Juranek

DOI: https://doi.org/10.1097/00006454-199112000-00005

1991-12-01

The Pediatric Infectious Disease Journal

Abstract:&NA; Risk factors for the introduction, spread and persistence of Cryptosporidium and Giardia lamblia infections in child day‐care centers are not well understood. In 1989 and 1990 stool specimens were obtained from 292 diapered children attending 17 randomly selected daycare centers in Fulton County, GA; 8 (2.7%) children in 2 centers were infected with Cryptosporidium and 21 (7.2%) children in 7 centers were infected with Giardia. In 1986 the prevalence of Cryptosporidium and Giardia in these same centers had been 0.4 and 11.0%, respectively; the prevalence of Cryptosporidium, but not Giardia, increased significantly (P = 0.04) between 1986 and 1989 to 1990. Risk factors for Giardia infection included day‐care attendance for >3 months, the presence of toddlers in the classroom and the presence of other children in the household. Day‐care centers with a Giardia‐positive child in 1986 were not more likely to have an infected child in 1989 to 1990. Cryptosporidium, like Giardia, may be endemic in day‐care centers in Fulton County.
Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages

Bradley K. Ackerson,Katia J. Bruxvoort,Lei Qian,Lina S. Sy,Sijia Qiu,Julia E. Tubert,Gina S. Lee,Jennifer H. Ku,Ana Florea,Yi Luo,Radha Bathala,Julie Stern,Soon K. Choi,Harpreet S. Takhar,Michael Aragones,Morgan A. Marks,Evan J. Anderson,Cindy Ke Zhou,Tianyu Sun,Carla A. Talarico,Hung Fu Tseng,Bradley K. AckersonKatia J. BruxvoortLei QianLina S. SySijia QiuJulia E. TubertGina S. LeeJennifer H. KuAna FloreaYi LuoRadha BathalaJulie SternSoon K. ChoiHarpreet S. TakharMichael AragonesMorgan A. MarksEvan J. AndersonCindy Ke ZhouTianyu SunCarla A. TalaricoHung Fu Tsenga Department of Research and Evaluation,Kaiser Permanente Southern California,Pasadena,CA,USAb Department of Epidemiology,University of Alabama at Birmingham,Birmingham,AL,USAc Infectious Disease,Epidemiology,Moderna Inc,Cambridge,MA,USAd Epidemiology,AstraZeneca,Gaithersburg,MD,USAe Department of Health Systems Science,Kaiser Permanente Bernard J. Tyson School of Medicine,Pasadena,CA,USA

DOI: https://doi.org/10.1080/21645515.2024.2335052

2024-04-06

Human Vaccines & Immunotherapeutics

Abstract:Emerging SARS-CoV-2 sublineages continue to cause serious COVID-19 disease, but most individuals have not received any COVID-19 vaccine for >1 year. Assessment of long-term effectiveness of bivalent COVID-19 vaccines against circulating sublineages is important to inform the potential need for vaccination with updated vaccines. In this test-negative study at Kaiser Permanente Southern California, sequencing-confirmed BA.4/BA.5- or XBB-related SARS-CoV-2-positive cases (September 1, 2022 to June 30, 2023), were matched 1:3 to SARS-CoV-2-negative controls. We assessed mRNA-1273 bivalent relative (rVE) and absolute vaccine effectiveness (VE) compared to ≥2 or 0 doses of original monovalent vaccine, respectively. The rVE analysis included 20,966 cases and 62,898 controls. rVE (95%CI) against BA.4/BA.5 at 14–60 days and 121–180 days was 52.7% (46.9–57.8%) and 35.5% (−2.8–59.5%) for infection, and 59.3% (49.7–67.0%) and 33.2% (−28.2–68.0%) for Emergency Department/Urgent Care (ED/UC) encounters. For BA.4/BA.5-related hospitalizations, rVE was 71.3% (44.9–85.1%) and 52.0% (−1.2–77.3%) at 14–60 days and 61–120 days, respectively. rVE against XBB at 14–60 days and 121–180 days was 48.8% (33.4–60.7%) and −3.9% (−18.1–11.3%) for infection, 70.7% (52.4–82.0%) and 15.7% (−6.0–33.2%) for ED/UC encounters, and 87.9% (43.8–97.4%) and 57.1% (17.0–77.8%) for hospitalization. VE and subgroup analyses (age, immunocompromised status, previous SARS-CoV-2 infection) results were similar to rVE analyses. rVE of mRNA-1273 bivalent vaccine against BA.4/BA.5 and XBB infections, ED/UC encounters, and hospitalizations waned over time. Periodic revaccination with vaccines targeting emerging variants may be important in reducing COVID-19 morbidity and mortality.

immunology,biotechnology & applied microbiology
Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study

Susana Monge,James Humphreys,Nathalie Nicolay,Toon Braeye,Izaak Van Evercooren,Christian Holm Hansen,Hanne‐Dorthe Emborg,Chiara Sacco,Alberto Mateo‐Urdiales,Jesús Castilla,Iván Martínez‐Baz,Brechje de Gier,Susan Hahné,Hinta Meijerink,Anja Bråthen Kristoffersen,Ausenda Machado,Patricia Soares,Anthony Nardone,Sabrina Bacci,Esther Kissling,Baltazar Nunes,VEBIS‐EHR Working Group

DOI: https://doi.org/10.1111/irv.13292

2024-04-25

Influenza and Other Respiratory Viruses

Abstract:Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID‐19 hospitalisation and death in booster‐eligible ≥ 65‐year‐olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID‐19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65‐ to 79‐year‐olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80‐year‐olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.

infectious diseases,virology

Right-sided origin of the left main coronary artery: typical variants and their visualization by cardiac computerized tomography.

Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024

Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity — IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024

Effectiveness Over Time of a Primary Series of the Original Monovalent COVID-19 Vaccines in Adults in the United States

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021

Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking.

Effectiveness of the Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters in Pregnant Persons Who Were Not Immunocompromised: VISION Network, June 2022-August 2023

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents

Effectiveness of the original monovalent mRNA COVID-19 vaccination series against hospitalization for COVID-19-associated venous thromboembolism

Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023

Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study

Giardia lamblia and Cryptosporidium infections in child day‐care centers in Fulton County, Georgia

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages

Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study